MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. AGL
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

agilon health (AGL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

agilon health
NYSE•Healthcare•Medical Care Facilities
$89.16-0.01(<0.01%)Market closed
Market Cap
$1.49B
P/S
0.3x
P/B
6.5x

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.

C

How this company scores

AverageMetricSide Score: 53/100

Strongest: Balance Sheet & Red Flags (22/25); weakest: Cash & Earnings Quality (4/25).

Profitability15/25
Growth12/25
Balance Sheet & Red Flags22/25
Cash & Earnings Quality4/25
Strengths
Low leverageProfit converts from growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.3x5y range 0.0x – 5.9x
P/S 0.3x · below its 19-quarter median

Currently below its 19-quarter median.

P/B · 6.5x5y range 0.7x – 9.9x
P/B 6.5x · near its 20-quarter median

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume
Market Cap $1.49B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$5.92B
0%
Q. Revenue
$1.49B
7%
TTM EBITDA
$-281.28M
2Q
TTM Op. Income
$-309.33M
2Q
Q. Op. Income
$11.77M
2Q
TTM Net Income
$-232.22M
2Q
Q. Net Income
$17.96M
117%
EPS
$1.07
Shares Out.
$16.70M
7Q
$5.92B in TTM revenue grew 0.3% YoY, reaching $1.49B last quarter. TTM EBITDA of $-281.28M and TTM operating income of $-309.33M show growth is flowing through to the bottom line. However, net income is negative at $232.22M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
1.2%
2Q
Op. Margin
0.8%
2Q
Net Margin
1.2%
116%
Op. margin of 0.8% is up 9.1% YoY — cost efficiency is improving. Net margin at 1.2% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
0.3x
56%
P/B Ratio
6.5x
181%
P/S of 0.3x and P/B of 6.5x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$1.59B
2Q
Cash
$107.18M
2Q
Long-Term Debt
$15.38M
56%
Book Value
$227.53M
2Q
D/E Ratio
0.1
2Q
Debt/EBITDA
0.8
With $1.59B in assets and $15.38M in long-term debt, D/E is 0.1and book value is $227.53M — a conservative capital structure with a cushion to weather downturns. Across the last 5 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$-57.30M
63%
TTM Free Cash Flow
$-84.95M
18%
FCF Margin
-1.4%
17%
FCF / Net Income
0.4
60%
TTM FCF of $-84.95M on $-57.30M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 18% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Cash Burn

Red Flag

The last 4 consecutive quarters had negative FCF — the company is burning cash and may need external funding.